Abstract Background This exploratory sub-analysis of the EMPA-HEART CardioLink-6 trial examined whether the previously reported benefit of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on left ventricular (LV) mass (LVM) regression differs between individuals of South Asian and non-South Asian ethnicity. Methods EMPA-HEART CardioLink-6 was a double-blind. placebo-... https://www.roneverhart.com/HP-Victus-15L-TG02-0325m-Gaming-Desktop-AMD-Ryzen-7-5700G-3-8-GHz-Radeon-RX-6400-32GB-DDR4-1TB-SSD-Windows-11-Home-Mi/